In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 54 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Stress-induced growing prevalence of secondary aldosteronism among patients with coronary artery disease and chronic heart failure

Session Poster Session 3

Speaker Victoriia Venzhega

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure - Epidemiology, Prognosis, Outcome
  • Session type : Poster Session

Authors : VV Venzheha (Donetsk,UA), PO Shevelok (Donetsk,UA), AN Shevelok (Donetsk,UA), NT Vatutin (Donetsk,UA)

VV Venzheha1 , PO Shevelok2 , AN Shevelok3 , NT Vatutin3 , 1M. Gorky Donetsk national medical University - Donetsk - Ukraine , 2Donetsk district hospital #7 - Donetsk - Ukraine , 3M. Gorky Donetsk national medical University, V. K. Gusak Institute of urgent and recovery surgery - Donetsk - Ukraine ,


Background/Introduction:  Numerous studies have shown that aldosterone plasma level is an independent predictor of cardiovascular complications in patients with coronary artery disease (CAD) and chronic heart failure (CHF). It is well known that chronic stress unfavorably affects hormonal secretion and can lead to increase in cortisol one, but its effect on aldosterone level remain unclear.

Purpose: We evaluated the impact of chronic stress on the prevalence of hyperaldosteronism among CHF patients and assessed the relationship between aldosterone plasma level and the risk of major cardiovascular complications.

Methods: The study included 286 patients with stable CAD and CHF undergoing inpatient treatment in cardiology department at V. K. Gusak Institute of emergency and reconstructive surgery the from January 1, 2015 to December 31, 2017, in the period of military conflict in war-zone of  Donbass region.  Clinical characteristics and plasma aldosterone level of this group were compared with those of 218 CHF patients comparable for age and gender treated in the same hospital in previous peacetime 2012-2013 years. The primary endpoint consists of major cardiovascular events during 12 month after discharge.

Results: High plasma aldosterone level (>160 pg/ml) was found in 27.6 % of wartime patients and 15.6 % of peacetime patients (odds ratio (OR) = 2.1; 95% confidence interval (CI) 1.3 to 3.2).  Primary aldosteronism was diagnosed in 2.6 % and 0.9 % of wartime and peacetime patients, respectively (OR = 2.7; 95% CI 0.6 to 13.2). The occurrence of major cardiovascular events (non-fatal myocardial infarction, percutaneous coronary intervention, stroke, new-onset or recurrence of atrial fibrillation, acute heart failure) during 12-months follow-up period was significantly higher during wartime compared to peacetime (OR = 2.6; 95% CI 1.7 to 4.3). The rate of fatal cardiovascular complications was comparable in both groups. High aldosterone plasma level was the independent risk factor of cardiovascular events in Cox regression models adjusted for covariates (OR = 3.2, 95 % CI 2.1 to 5.8 for aldosterone > 160 pg/ml).

Conclusions: Chronic stress leads to growing prevalence of secondary aldosteronism among patients with CAD and CHF. High plasma aldosterone level is associated with increased frequency of cardiovascular events independent of major established risk factors.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are